Is Neuropace Stock a good buy in 2023, according to Wall Street analysts?
The consensus among 1 Wall Street analyst covering (NASDAQ: NPCE) stock is to Hold NPCE stock.
Out of 1 analyst, 0 (0%) are recommending NPCE as a Strong Buy, 0 (0%) are recommending NPCE as a Buy, 1 (100%) are recommending NPCE as a Hold, 0 (0%) are recommending NPCE as a Sell, and 0 (0%) are recommending NPCE as a Strong Sell.
What is NPCE's forecast return on equity (ROE) for 2023-2025?
(NASDAQ: NPCE) forecast ROE is -208.33%, which is considered weak.
What is NPCE's Price Target?
According to 1 Wall Street analyst that have issued a 1 year NPCE price target, the average NPCE price target is $6.00, with the highest NPCE stock price forecast at $6.00 and the lowest NPCE stock price forecast at $6.00.
The Wall Street analyst predicted that Neuropace's share price could fall to $6.00 by Aug 24, 2024. The average Neuropace stock price prediction forecasts a potential downside of 23.95% from the current NPCE share price of $7.89.
What is NPCE's forecast return on assets (ROA) for 2023-2025?
(NASDAQ: NPCE) forecast ROA is -43.25%, which is lower than the forecast US Medical Devices industry average of 11.73%.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.